Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Accumulated Expenses (2020 - 2022)

Kiora Pharmaceuticals (KPRX) has disclosed Other Accumulated Expenses for 3 consecutive years, with $15630.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Other Accumulated Expenses changed N/A year-over-year to $15630.0, compared with a TTM value of $15630.0 through Sep 2022, changed N/A, and an annual FY2021 reading of $28961.0, down 77.33% over the prior year.
  • Other Accumulated Expenses was $15630.0 for Q3 2022 at Kiora Pharmaceuticals, down from $28961.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $127730.0 in Q4 2020 and bottomed at $15630.0 in Q3 2022.
  • Average Other Accumulated Expenses over 3 years is $57440.3, with a median of $28961.0 recorded in 2021.
  • Peak annual rise in Other Accumulated Expenses hit 77.33% in 2021, while the deepest fall reached 77.33% in 2021.
  • Year by year, Other Accumulated Expenses stood at $127730.0 in 2020, then plummeted by 77.33% to $28961.0 in 2021, then crashed by 46.03% to $15630.0 in 2022.
  • Business Quant data shows Other Accumulated Expenses for KPRX at $15630.0 in Q3 2022, $28961.0 in Q4 2021, and $127730.0 in Q4 2020.